| Literature DB >> 33171743 |
Ana Daniela Batista1, Daniela A Rodrigues2, Adolfo Figueiras3,4,5, Maruxa Zapata-Cachafeiro3,4, Fátima Roque2,6, Maria Teresa Herdeiro7.
Abstract
Antibiotic resistance still remains a major global public health problem and the dispensing of antibiotics without a prescription at community pharmacies is an important driver of this. MEDLINE, Pubmed and EMBASE databases were used to search and identify studies reporting the dispensing of non-prescribed antibiotics in community pharmacies or drugstores that sell drugs for human use, by applying pharmacy interviews/questionnaires methods and/or simulated patient methods. Of the 4683 studies retrieved, 85 were included, of which 59 (69.4%) were published in low-and middle-income countries. Most of the papers (83.3%) presented a percentage of antibiotic dispensing without a prescription above 60.0%. Sixty-one studies evaluated the active substance and the most sold antibiotics without a prescription were amoxicillin (86.9%), azithromycin (39.3%), ciprofloxacin (39.3%), and amoxicillin-clavulanic acid (39.3%). Among the 65 articles referencing the diseases/symptoms, this practice was shown to be mostly associated with respiratory system problems (100.0%), diarrhea (40.0%), and Urinary Tract Infections (30.8%). In sum, antibiotics are frequently dispensed without a prescription in many countries and can thus have an important impact on the development of resistance at a global level. Our results indicate the high need to implement educational and/or regulatory/administrative strategies in most countries, aiming to reduce this practice.Entities:
Keywords: antibiotics; non-prescription antibiotic dispensing; pharmacy practice; self-medication
Year: 2020 PMID: 33171743 PMCID: PMC7694985 DOI: 10.3390/antibiotics9110786
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Study selection flowchart.
Characteristics of the selected studies.
| Authors | Year of Publication | Country | Study Design | Data Collection Method | Quality Assesment a | Criteria not Fulfilled a |
|---|---|---|---|---|---|---|
| Abubakar U. et al. [ | 2020 | Nigeria | Cross-sectional prospective study | Pharmacy interviews/questionnaires | High | 7 |
| Abubakar U. [ | 2020 | Nigeria | Cross-sectional study | Pharmacy interviews/questionnaires | High | 6, 7, 13 |
| Al-Tannir M. et al. [ | 2020 | Saudi Arabia | Cross-sectional study | Simulated patient method | High | 7, 12, 14 |
| Badro D.A. et al. [ | 2020 | Lebanon | Cross-sectional study | Pharmacy interviews/questionnaires | High | 3, 7, 14 |
| Bahta M. et al. [ | 2020 | Eritrea | Cross-sectional study | Simulated patient method | High | 7, 13, 14 |
| Chen J. et al. [ | 2020 | China | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Gajdács M. et al. [ | 2020 | Hungary | Cross-sectional study | Pharmacy interviews/questionnaires | High | 3, 7, 14 |
| Halboup A. et al. [ | 2020 | Yemen | Cross-sectional study | Simulated patient method | High | 14 |
| Shi L. et al. [ | 2020 | China | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Wang X. et al. [ | 2020 | China | Cross-sectional study | Simulated patient method | High | 12, 14 |
| Abdelaziz AI et al. [ | 2019 | Egypt | Cross-sectional study | Simulated patient method | High | 14 |
| Alrasheedy AA. et al. [ | 2019 | Saudi Arabia | Cross-sectional study | Simulated patient method and pharmacy interviews/qestionnaires | Medium | 6, 7, 12, 14 |
| Chang J. et al. [ | 2019 | China | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Damisie G et al. [ | 2019 | Ethiopia | Cross-sectional study | Simulated patient method | Medium | 3, 7, 10, 14 |
| Hallit S et al. [ | 2019 | Lebanon | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 13 |
| Koji EM et al. [ | 2019 | Ethiopia | Cross-sectional prospective study | Simulated patient method | High | 7, 14 |
| Mengistu G et al. [ | 2019 | Ethiopia | Cross-sectional study | Simulated patient method and pharmacy interviews/questionnaires | High | 7, 14 |
| Nafade V. et al. [ | 2019 | India | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Zawahir S et al. [ | 2019 | Sri Lanka | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Zawahir S. et al. [ | 2019 | Sri Lanka | Cross-sectional study | Pharmacy interviews/questionnaires | High | 14 |
| Ajie A.A.D. et al. [ | 2018 | Indonesia | Cross-sectional study | Pharmacy interviews/questionnaires | High | 18 |
| Alhomoud F et al. [ | 2018 | Saudi Arabia | Qualitative exploratory study | Pharmacy interviews/questionnaires | Medium | 6, 7, 13, 14 |
| Awosan KJ et al. [ | 2018 | Nigeria | Cross-sectional study | Pharmacy interviews/questionnaires | High | 13, 14 |
| Erku D.A. et al. [ | 2018 | Ethiopia | Cross-sectional study | Simulated patient method | High | 3, 7, 14 |
| Horumpende PG et al. [ | 2018 | Tanzania | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Ibrahim IR et al. [ | 2018 | Iraq | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Mohamed Ibrahim M.I. et al. [ | 2018 | Qatar | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Paes M.R. et al. [ | 2018 | India | Cross-sectional study | Pharmacy interviews/questionnaires | Medium | 3, 7, 10, 11, 12, 14 |
| Rehman IU et al. [ | 2018 | Pakistan | Cross-sectional study | Pharmacy interviews/questionnaires | Medium | 3, 7, 13, 14 |
| Sarwar M.R. et al. [ | 2018 | Pakistan | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Zapata-Cachafeiro M et al. [ | 2018 | Spain | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Zawahir S et al. [ | 2018 | Sri Lanka | Cross-sectional study | Simulated patient method | High | 14 |
| Ansari M. [ | 2017 | Nepal | Cross-sectional prospective study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Barker A.K. et al. [ | 2017 | India | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Chang J. et al. [ | 2017 | China | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Jaisue S. et al. [ | 2017 | Thailand | Cross-sectional study | Simulated patient method | Medium | 3, 7, 10, 14, 18 |
| Mansour O. et al. [ | 2017 | Syria | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 13 |
| Marković-Peković V et al. [ | 2017 | Republic of Srpska and Herzegovina | Cross-sectional study | Simulated patient method | High | 7, 14, 18 |
| Okuyan B. et al. [ | 2017 | Turkey | Cross-sectional study | Simulated patient method | High | 7, 14, 18 |
| Abegaz T.M. et al. [ | 2016 | Ethiopia | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Abood EA et al. [ | 2016 | Yemen | Cross-sectional study | Pharmacy interviews/questionnaires | High | 3, 7, 14 |
| Erku D.A. [ | 2016 | Ethiopia | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Guinovart MC et al. [ | 2016 | Spain | Prospective study | Simulated patient method | Medium | 3, 7, 10, 14, 18, 20 |
| Ibrahim M.I.B.M. et al. [ | 2016 | Qatar | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Kalungia AC et al. [ | 2016 | Zambia | Descriptive cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Khan M.U. et al. [ | 2016 | Malaysia | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 13, 14 |
| Nawab A. et al. [ | 2016 | Pakistan | Cross-sectional study | Pharmacy interviews/questionnaires | Medium | 6, 7, 10, 12, 14, 18 |
| Satyanarayana S. et al. [ | 2016 | India | Cross-sectional study | Simulated patient method | High | 6, 7, 14 |
| Almaaytah A et al. [ | 2015 | Jordan | Prospective study | Simulated patient method | Medium | 7, 10, 14, 18 |
| Bahnassi A. [ | 2015 | Syria | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 10, 18 |
| Dorj G. et al. [ | 2015 | Mongolia | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Shet A et al. [ | 2015 | India | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Shreya Svitlana A. et al. [ | 2015 | India | Cross-sectional study | Pharmacy interviews/questionnaires | Low | 6, 7, 9, 10, 11, 12, 14, 18, 20 |
| Alabid A.H.M.A. et al. [ | 2014 | Malaysia | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Bahnassi A. [ | 2014 | Saudi Arabia | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Farah R et al. [ | 2014 | Lebanon | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14, 20 |
| Gastelurrutia M.A. et al. [ | 2014 | Spain | Prospective study | Pharmacy interviews/questionnaires | Medium | 3, 7, 10, 11, 14 |
| Sabry NA et al. [ | 2014 | Egypt | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7 |
| Zapata-Cachafeiro M. et al. [ | 2014 | Spain | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 9, 14 |
| Abasaeed AE et al. [ | 2013 | United Arab Emirates | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14 |
| Malik M. et al. [ | 2013 | Pakistan | Cross-sectional study | Simulated patient method | High | 3, 7, 18 |
| Minzi O et al. [ | 2013 | Tanzania | Cross-sectional study | Simulated patient method | High | 7, 9, 14 |
| Marković-Peković V et al. al. [ | 2012 | Republic of Srpska and Herzegovina | Cross-sectional study | Simulated patient method | Medium | 3, 7, 10, 14, 20 |
| Rathnakar U.P. et al. [ | 2012 | India | Prospective study | Simulated patient method | High | 7, 14, 18 |
| Simó S et al. [ | 2012 | Spain | Prospective study | Simulated patient method | Medium | 7, 12, 14, 20 |
| Al-Faham Z et al. [ | 2011 | Syria | Cross-sectional study | Simulated patient method | High | 7, 10, 20 |
| Al-Mohamadi A et al. [ | 2011 | Saudi Arabia | Cross-sectional study | Simulated patient method | Medium | 7, 9, 14, 18, 20 |
| Puspitasari HP et al. [ | 2011 | Indonesia | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Hadi U et al. [ | 2010 | Indonesia | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Llor C et al. [ | 2010 | Spain | Prospective study | Simulated patient method | Medium | 3, 7, 14, 20 |
| Plachouras D et al. [ | 2010 | Greece | Quantitative study | Simulated patient method | Medium | 6, 7, 14, 18, 20 |
| Saengcharoen W. et al. [ | 2010 | Thailand | Cross-sectional study | Simulated patient method | High | 7, 14 |
| Llor C et al. [ | 2009 | Spain | Prospective study | Simulated patient method | Medium | 3, 7, 14, 20 |
| Rauber C. et al. [ | 2009 | Brazil | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 9, 14 |
| Viberg N et al. [ | 2009 | Tanzania | Cross-sectional study | Simulated patient method | High | 7, 14, 18 |
| Nyazema N et al. [ | 2007 | Zimbabwean | Cross-sectional study | Simulated patient method and Pharmacy interviews/questionnaires | High | 7, 13, 14 |
| Caamaño F et al. [ | 2005 | Spain | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 14, 20 |
| Volpato DE et al. [ | 2005 | Brazil | Cross-sectional study | Simulated patient method | Medium | 7, 9, 10, 20 |
| Caamano Isorna F. et al. [ | 2004 | Spain | Cross-sectional study | Pharmacy interviews/questionnaires | High | 7, 20 |
| Larson E et al. [ | 2004 | United States of America | Cross-sectional study | Simulated patient method | Medium | 7, 14, 17, 18, 20 |
| Chalker J et al. [ | 2002 | Vietnam | Intervention study | Pharmacy interviews/questionnaires | High | 7 |
| Al-Ghamdi MS. [ | 2001 | Saudi Arabia | Cross-sectional study | Simulated patient method | Medium | 3, 7, 10, 14, 18, 20 |
| Chalker J et al. [ | 2000 | Vietnam | Cross-sectional study | Simulated patient method | High | 7, 10, 14 |
| Wachter DA et al. [ | 1999 | Nepal | Cross-sectional study | Simulated patient method | High | 7, 14, 20 |
| Wolffers I. [ | 1987 | Sri Lanka | Cross-sectional study | Simulated patient method | Low | 3, 5, 7, 9, 10, 11, 12, 14, 18, 20 |
a Quality Assessment, Quality assessment carried out using the Appraisal tool for Cross-Sectional Studies (AXIS).
Study Outcomes—Articles that use the simulated patient method.
| Authors (Year) | Sample Size | Frequency of Antibiotic Dispensation without a Prescription | Name/Class of Antibiotics Most Often Dispensed without a Prescription | Types of Disease/Symptoms Most Commonly Associated with Dispensation without a Prescription | Level of Insistence by Patients and the Percentage of Antibiotic Dispensation without a Prescription at Each Level |
|---|---|---|---|---|---|
| Al-Tannir M. et al. (2020) [ | Sore throat, acute sinusitis, otitis media, acute bronchitis, diarrhea, and UTI | Three levels of demand: level 1 (Can I have something to relieve my symptoms?), level 2 (Can I have something stronger?), level 3 (I would like to have an antibiotic.) | |||
| Sore throat, acute sinusitis, otitis media, acute bronchitis, diarrhea, and UTI | Three levels of demand: level 1 (Can I have something to relieve my symptoms?), level 2 (Can I have something stronger?), level 3 (I would like to have an antibiotic.). | ||||
| Bahta M. et al. (2020) [ | 153 V | 87.6% | Ciprofloxacin (n = 65, 47.8%), cotrimoxazole (n = 51, 37.5%), amoxicillin (n = 11, 8.1%), doxycycline (n = 5, 3.7%), tinidazole (n = 3, 2.2%) and metronidazole (n = 1, 0.7%). | UTI and acute watery diarrhea | Three levels of demand: level 1 (Asked for some drugs to alleviate the symptoms) (81.3%), level 2 (Request for unspecified antibiotics) (11.2%), level 3 (Ask pharmacy attendant for a specific type of antibiotics) (6.7%) |
| Chen J. et al. (2020) [ | 1106 PH | 83.6%, n = 925 | Penicillins (n = 333, 36.0%), cephalosporins (n = 274, 29.6%), macrolides (n = 250, 27.0%) | Mild upper respiratory tract symptoms (young adult) | Three levels of demand: level 1 (Symptoms only described) (25.2%), level 2 (Asked for antibiotics) (52.1%), level 3 (Asked for penicillin or cephalosporins) (6.3%). |
| Halboup A. et al. (2020) [ | 1000 PH, 200 each scenario | 73.3%, n = 733 | Penicillin (48.3%), sulfonamide (12.5%), macrolide (10.6%), fluoroquinolones (8.8%), chloramphenicol (0.3%) | Sore throat, otitis media, cough, diarrhea, and UTI | Three different levels of demand: level 1 (Asked for medications to relieve the symptoms), level 2 (Asked for a stronger medication), level 3 (Asked for an antibiotic) |
| Shi L. et al. (2020) [ | 147 PH | 88.4%, n = 130 | Pediatric and adult acute cough associated with a common cold | Three levels of demand: level 1 (Client required some medicine for cough) (22.5%), level 2 (Client explicitly expressed the requirement of antibiotics) (60.5%), level 3 (Client specifically required roxithromyci) (5.4%) | |
| Wang X. et al. (2020) [ | 120 PH/V | 73.3%, n = 88 | Norfloxacin (n = 60), gentamicin (n = 13), levofloxacin (n = 8), ciprofloxacin hydrochloride (n = 8), cefotaxime (n = 1), oxytetracycline (n = 1) and trimethoprim (n = 1) | Acute diarrhea | Two levels of demand: level 1 (“Hi, I have suffered from diarrhea since yesterday, please give me some medicine.”) (55%), level 2 (“Hi, I have suffered from diarrhea since yesterday, and I am here to buy antibiotics.”) (91.7%) |
| Abdelaziz AI et al. (2019) [ | 238 PH (acute bronchitis: 125, common cold: 113) | 98.4% | Amoxicillin: acute bronchitis: 97.6%, common cold: 99.1%. | Acute bronchitis and common cold | |
| Alrasheedy AA. et al. (2019) [ | 116 PH, 58 each scenario | 92.15% | Pharyngitis and UTI | Three levels of demand: level 1 (Asked for something to relieve the symptoms), level 2 (Asked for something stronger), level 3 (Simulated patient directly requested an antibiotic) | |
| Chang J. et al. (2019) [ | 2411 PH, 4822 INT | 59.3% | Amoxicillin and cephalosporins | Paediatric diarrhoea and adult acute URTI | Three levels of demand: level 1 (“Can you give me some medicine to alleviate the patient’s symptoms?”), level 2 (“Can you give me some antibiotics?”), level 3 (“I would like some amoxicillin or cephalosporins.”) |
| Damisie G et al. (2019) [ | 18 DS | 94.4%, n = 17 | Sore throat, | Three levels of demand: level 1 (Asking something to alleviate his/her symptoms), level 2 (Asking for a stronger medication), level 3 (Clear request for an antibiotic in the case of not achieving the previous two levels of demand) | |
| Koji EM et al. (2019) [ | 262 PH | 63.4%, n = 166 | Amoxicillin, amoxicillin-clavulanate, azithromycin, trimethoprim/sulfamethoxazole, metronidazole, ceftriaxone, cloxacillin, vancomycin, ampicillin, cefotaxime, gentamicin | Common cold, acute onset diarrhea, pneumonia (child), meningitis (child) | |
| Mengistu G et al. (2019) [ | 105 PH | 86.7% | Cotrimoxazole (97.8%) | Acute watery diarrhea (child) | |
| Nafade V. et al. (2019) [ | 279 PH, 1522 INT (761 each scenario) | 4.0% | URTI, uncomplicated acute diarrhoea, and acute febrile illness suggestive of malaria | ||
| Zawahir S et al. (2019) [ | 242 PH | 41.0%, n = 99 | Viral infections: | Three levels of demand: level 1 (Can I get some medicine to alleviate the symptoms?) (n = 39, 16%), level 2 (Can I get something stronger?) (n = 33, 14%), level 3 (I would like an antibiotic.) (n = 27, 11%). | |
| Erku D.A. et al. (2018) [ | 50 CMRO, 100 V | 86.0%, n = 86 | Acute childhood diarrhea and URTI | ||
| Horumpende PG et al. (2018) [ | 82 PH (26 class I, 56 class II) | 92.3% | Amoxycillin (n = 1), ampiclox (n = 3), trimethoprim/sulphamethoxazole (n = 2), cefixime (n = 1), amoxyclav, (n = 1), azithromycin (n = 4), erythromycin (n = 1), metronidazole | Fever, diarrhoea, runny nose, painful urination, and cough | |
| Ibrahim IR et al. (2018) [ | 75 PH | 20.0%, n = 15 | Metronidazole (n = 4, 5.3%), furazolidone (n = 3, 4.0%) | Acute diarrhea | |
| Mohamed Ibrahim M.I. et al. (2018) [ | 25 PH | 5.0% | Common cold (signs and symptoms: sore throat, slight cough, tiredness and body aches), and allergic rhinitis (signs and symptoms: running nose or congestion, sneezing, slight sore throat with phlegm and slight cough when in bed) | ||
| Zapata-Cachafeiro M et al. (2018) [ | 977 PH | 18.8%, n = 184 | Amoxicillin (n = 127, 69.0%), amoxicillin-clavulanic acid (7%), azithromycin (n = 42, 22.8%), cotrimoxazole (n = 7, 3.8%), moxifloxacin (n = 4, 2.2%), cefuroxime (n = 2, 1.1%), clarithromycin (n = 1, 0.5%) and clindamycin (n = 1, 0.5%) | Sore throat, difficulty swallowing, and feeling feverish, in addition to congestion and cough | Four levels of demand: level 1 (Request for medication to relieve the symptoms) (2.97%), level 2 (Request for a stronger medication than that offered) (4.22%), level 3 (Request for an antibiotics) (4.52%), level 4 (Specific request for amoxicillin) (8.54%) |
| Zawahir S et al. (2018) [ | 242 PH | 61.0%, n = 147 | Ciprofloxacin (n = 44, 70%), erythromycin, metronidazole, amoxicillin (n = 32, 52%) | URTI (adult and child), watery diarrhoea and UTI | |
| Chang J. et al. (2017) [ | 256 PH | 66.8% | Paediatric diarrhoea and adult acute URTI | Three levels of demand: level 1 (“Can you give me some drugs to alleviate the symptoms of the disease?”), level 2 (“Can you give me some antibiotics?”), level 3 (“I would like some amoxicillin or cefaclor.”) | |
| Jaisue S. et al. (2017) [ | 91 class I PH | 68.1%, n = 62 | Furazolidone (n = 31, 34.1%), nifuroxazide (n = 17, 18.7%), cotrimoxazole (n = 10, 11.0%), metronidazole (n = 2, 2.2%), cephalexin (n = 2, 2.2%), azithromycin (n = 1, 1.1%), norfloxacin (n = 1, 1.1%) | Non-infectious diarrhoea in a 14-month-old child | |
| Marković-Peković V et al. (2017) [ | URTI | ||||
| URTI | |||||
| Okuyan B. et al. (2017) [ | 70 PH | Antibiotic + NSAIDs (n = 15, 21.4%) | Cefuroxime alone (n = 5), cefuroxime with other medication (n = 6), amoxicillin-clavulanic acid alone (n = 12), amoxicillin-clavulanic acid with other medication (n = 9) | Acute uncomplicated rhinosinusitis | |
| Abegaz T.M. et al. (2016) [ | 113 PH | 51.3%, n = 58 | Cotrimoxazole and metronidazole | Acute diarrhea | |
| Guinovart MC et al. (2016) [ | 220 PH | 54.1%, n = 119 | β-lactam antibiotic and amoxicillin-clavulanic acid | UTI, sore throat, and acute bronchitis | Four levels of demand: level 1 (Medication to treat the symptoms was required), level 2 (A stronger medication was required), level 3 (An antibiotic was required), level 4 (A specific antibiotic was required: amoxicillin/clavulanic acid for a UTI and amoxicillin for a sore throat and acute bronchitis) |
| Ibrahim M.I.B.M. et al. (2016) [ | 30 PH | 43.2%, n = 41 | Nifuroxazide (n = 21, 22.11%), metronidazole alone (n = 12, 12.63%), metronidazole with other medication (n = 4, 4.21%), tinidazole (n = 2, 2.11%), furazolidone (n = 1, 1.05%) | Acute gastroenteritis | |
| Satyanarayana S. et al. (2016) [ | 622 PH, 1200 V | 27.0%, n = 319 | Tuberculosis | ||
| Almaaytah A et al. (2015) [ | 202 PH | 74.3%, n = 150 | Sore throat, otitis media, acute sinusitis, diarrhea, and UTI | Three levels of demand: level 1 (Asking for something to alleviate the symptoms) (n = 121, 59.9%), level 2 (Asking for a stronger medication) (n = 4, 2%), level 3 (Clear request for an antibiotic) (n = 25, 12.4%) | |
| Shet A et al. (2015) [ | 261 PH | 66.7%, n = 174 | URTI (adult) and acute gastroenteritis (child) | Two levels of demand: level 1 (Request for a “medicine” to alleviate the described symptoms) (55.6%), level 2 (Specifically asked for a “stronger” medicine) (44.4%) | |
| Alabid A.H.M.A. et al. (2014) [ | 50 PH/Ph, 100 V | 32.0%, n = 32 | Amoxil and Amoxiclav (n = 11, 11.0%), erythromycin (n = 9, 9.0%), cefalexin (n = 4, 4.0%) | Common cold symptoms (symptoms of URTI) | |
| Malik M. et al. (2013) [ | 238 PH/V | Simulated patients were treated in 198 V (83.1%); antibiotics were given in 69 V (34.4%) | Uncomplicated malaria fever | ||
| Minzi O et al. (2013) [ | 85 ADDO and 60 DLDB | 67.0% | Ciprofloxacin, amoxicillin, ampicillin, chloramphenicol, procaine penicillin, tetracycline | Cough, headache and diarrhea (“typhoid”, child), injured on the left hip by a piece of metal, fever and diarrhea (“cholera”, child), vomiting and diarrhea (“typhoid”, child), cough (“Pneumonia”), UTI, complaining of yellowish urethral discharge with a bad smell (“gonorrhea”) | |
| Marković-Peković V et al. (2012) [ | 131 PH | 58.0%, 76 pharmacies | Amoxicillin (85%), doxycyline (5%), ampicillin (7%), and cefalexin (3%) | URTI | Without insistence in case of refusal |
| Rathnakar U.P. et al. (2012) [ | 60 PH, 20 for each scenario | 51.7%, n = 31 | Amoxicillin (n = 19, 31.7%), erythromycin (n = 1, 1.7%), ampicillin+cloxacillin (n = 1, 1.7%), azithromycin (n = 4, 6.7%) | URTI, acute bronchitis, and diarrhoea | Two levels of demand: Level 1 (Can I have something for my symptoms?) and level 2 (I would like an antimicrobial agents.) |
| Simó S et al. (2012) [ | 50 PH | 8.0%, n = 4 | Amoxicillin/clavulanic acid (n = 4, 8%) | URTI symptoms and fever | |
| Al-Faham Z et al. (2011) [ | 200 PH | 97.0%, n = 194 | Amoxicillin/clavulanic acid 1000 mg (n = 73, 37.6%); amoxicillin (n = 45, 23.1%); amoxicillin/clavulanic acid 625 mg (n = 25, 12.8%); amoxicillin/floxacillin (n = 13, 6.7%), cefodroxil (n = 13, 6.7%), clarithromycin (n = 6, 3.0%), azithromycin (n = 5, 2.5%), ciproflaxacillin (n = 4, 2.0%), Cloxacillin/Ampicillin (n = 4, 2.0%), cefixime (n = 2, 1.0%), cefprodoxime 100mg (n = 2, 1.0%) and cefprodoxime 200mg (n = 2, 1.0%) | Sinusitis (fever, runny nose with clear secretion and a headache in the frontal sinus region) | Two levels of demand: level 1 (without insistence) (n = 174, 87%), level 2 (with insistence) (n = 20, 10%) |
| Al-Mohamadi A et al. (2011) [ | 60 PH/Ph | 97.9% | Co-amoxiclav (Augmentin), amoxicillin-clavulanic acid, cefaclor | Sore throat | |
| Puspitasari HP et al. (2011) [ | 264 PH/V, 88 for each scenario | 91.0%, n = 80 | Ciprofloxacin (n = 80, 91%), tetracycline (n = 80, 91%), amoxicillin (n = 74, 84%) | “discomfort on urination”, infected leg wounds and “productive cough, rainy nose, fever and lost of appetite” | |
| Hadi U et al. (2010) [ | 104 MRO (75 PH, 28 K, 1 DS) | 75.9%, n = 79 | Amoxicillin (n = 15), chloramphenicol (n = 18), ciprofloxacin (n = 14), cotrimoxazole (n = 14), tetracycline 250 mg (n = 15), tetracycline 500 mg (n = 2) | ||
| Llor C et al. (2010) [ | 197 PH (sore throat: 69, acute bronchitis: 59, UTI: 69) | 45.2%, n = 89 | Sore throat, acute bronchitis, and UTI | Three levels of demand: level 1 (Asked for something to alleviate the symptoms of the infection), level 2 (“This medication is not very strong, can’t you give me something stronger?”), level 3 (Asking openly for an antibiotic) | |
| Plachouras D et al. (2010) [ | 174 PH/V (ciprofloxacin: 102, amoxicillin + clavulanic acid: 72) | 72.4%, n = 126 | Ciprofloxacin (n = 54, 53%), amoxicillin/clavulanic acid (n = 72, 100%) | Without insistence in case of refusal | |
| Saengcharoen W. et al. (2010) [ | 115 PH (type I: 96 and type II: 19) | Pharmacy personnel: Nifuroxazide, cotrimoxazole, norfloxacin, erythromycin and amoxicillin | Acute childhood diarrhoea | ||
| Llor C et al. (2009) [ | 197 PH (sore throat: 69, acute bronchitis: 59, UTI: 69) | 45.2%, n = 89 | Sore throat, acute bronchitis, and uncomplicated UTI | Three levels of demand: level 1 (“Can you give me something to alleviate the symptoms of the infection?”) (n = 65, 33.0%), level 2 (“Can’t you give me something stronger?”) (n = 17, 8.6%), level 3 (“I would like an antibiotic.”) (n = 7, 3.6%) | |
| Viberg N et al. (2009) [ | SCM-female: 144 V and SCM-male: 107 V | 55.5% | Abnormal vaginal discharge and itching (SCM-female), urethral discharge (SCM-male) | ||
| Nyazema N et al. (2007) [ | STI female: 57 V | 8.0% | Vaginal discharge and itching (STI female), urethral discharge (STI male) and acute diarrhoea (child) | ||
| Volpato DE et al. (2005) [ | 107 PH | 74.0% | Amoxicillin (n = 46, 74%), azythromycin (n = 6, 9.6%), sulfamethoxazole/trimethoprim (n = 5, 8.1%), cephalexin (n = 2, 3.2%), erythromycin (n = 2, 3.2%) and ampicillin (n = 1, 1.6%) | Acute and uncomplicated rhino-sinusitis | Three levels of demand: No insistence (58%), insisting once (13%) or twice (3%) when the antibiotic was denied. |
| Larson E et al. (2004) [ | 101 DS (PHN: 34, PBNHN: 37, PWNHN:30) | 50.0% | Ampicillin (n = 26, 76.5%), ampicillin and tetracycline (n = 2, 5.9%), ampicillin and erythromycin; amoxicillin (n = 2, 5.9%), erythromycin (n = 1, 2.9%) | Sore throat | |
| Al-Ghamdi MS. (2001) [ | 88 PH | 82.0%, n = 72 | Fluoroquinolones (First choice: n = 50, 69% and Second choice: n = 59, 87%), cotrimoxazole (First choice: n = 9, 13% and Second choice: n = 3, 4%), penicillins (First choice: n = 8, 11% and Second choice: n = 3, 4%), cephalosporins (First choice: n = 3, 4% and Second choice: n = 1, 2%), tetracyclins (First choice: n = 2, 3% and Second choice: n = 2, 3%) | Uncomplicated lower, UTI | |
| Chalker J et al. (2000) [ | 60 PH, 297 V | 81.5%, n = 242 | Tetracyclines (n = 36), amphenicols (n = 14), β-lactam antibacterials- Penicillins (n = 10), other β- lactam antibacterials (16), sulphonamides/trimethoprim (n = 6), macrolides and lincosamides (n = 15), quinolones (n = 188), metronidazole (n = 3), spectinomycin (n = 4), drugs for treatment of TB (n = 1) | STD | |
| Wachter DA et al. (1999) [ | 100 PH | 67.5% | Dysuria and acute watery diarrhoea (child) | ||
| Wolffers I. (1987) [ | 28 PH | 100.0% | Tetracyclin (100%) |
Sample size: PH, Pharmacies; Ph, Pharmacists; V, Visits; DS, DrugStores; MRO, Medicine Retail Outlets; INT, Interactions; DD, Drugs Dispensed; ADDO, Accredited Drug Dispensing Outlets; DLDB, Duka la Dowa Baridi; K, Kiosk; PHN, Primarily Hispanic Neighborhood; PBNHN, Primarily Black Non- Hispanic Neighborhood; PWNHN, Primarily White Non-Hispanic neighborhood; Types of disease/symptoms most commonly associated with dispensation without a prescription: UTI, Urinary Tract Infection; URTI, Upper Respiratory Tract Infection; STD, Sexually Transmitted Diseases; a Articles that do not explicitly mention throughout the full article that it is about dispensing antibiotics without a prescription, but rather the management of diseases/symptoms in pharmacies/drug stores; b Articles showing the frequency of dispensing antibiotics without a prescription for class I and class II pharmacies. Class I pharmacies are legally authorized to dispense antibiotics without a prescription.
Study Outcomes—articles that used the Pharmacy interviews/questionnaires.
| Authors (Year) | Sample Size | Frequency of Antibiotic Dispensation without a Prescription | Name/Class of Antibiotics Most Often Dispensed without a Prescription | Types of Disease/Symptoms Most Commonly Associated with Dispensation without a Prescription |
|---|---|---|---|---|
| Abubakar U. et al. (2020) [ | 98 Ph | PD: 74.5% (n = 73) | Penicillin (n = 84, 85.7%), tetracycline (n = 69, 70.4%), cephalosporin (n = 63, 64.3%), quinolone (n = 61, 62.2%), macrolides (n = 54, 55.1%), sulphonamides (n = 47, 48.0%), aminoglycosides (n = 34, 34.7%), carbapenems (n = 13, 13.3%. | UTI, typhoid fever, genital infections (gonorrhea), wound infections, eye infections, ear infections, diarrhea, malaria, toothache, and cold/flu |
| Abubakar U. (2020) [ | 98 Ph | PD: 96.9% (n = 95) | ||
| Badro D.A. et al. (2020) [ | 250 Ph | 88.0% acknowledged dispensing medications without a prescription, those medications included antibiotics (60.0%) | ||
| Gajdács M. et al. (2020) [ | 192 Ph | PD: 26.0% | ||
| Alrasheedy AA. et al. (2019) [ | 116 PH | 70.7%, n = 82 | ||
| Hallit S et al. (2019) [ | 280 PH, 202 Ph | 84.6% | Pharyngitis, otitis media, diarrhoea, and vomiting (child) | |
| Mengistu G et al. (2019) [ | 105 PH/PS | 50.5% | Acute watery diarrhea (child) | |
| Zawahir S. et al. (2019) [ | 265 PS | 31.7%, n = 84 | Acute sore throat, common cold, acute diarrhoea, wound infection, or uncomplicated UTI | |
| Ajie A.A.D. et al. (2018) [ | 190 PH | PD: 92.1% (n = 175) | Amoxicillin (n = 175, 92.1%), cotrimoxazole (n = 175, 92.1% and ciprofloxacin (n = 159, 83.7%) | |
| Alhomoud F et al. (2018) [ | 20 Ph | 100.0% | Amoxicillin/clavulanic Acid (Augmentin), | Fever, sore throat, cold/flu, and cough. |
| Awosan KJ et al. (2018) [ | 197 PS | PD: 91.9% (n = 181) | ||
| Paes M.R. et al. (2018) [ | 101 Ph | Dispensing without a prescription was 63.4% of the total dispensing encounters, those medications included antibiotics (5.8%) | ||
| Rehman IU et al. (2018) [ | 181 Ph | PD: 68.0% (n = 123) | ||
| Sarwar M.R. et al. (2018) [ | 400 Ph | PD: 93.7% (n = 375) | ||
| Ansari M. (2017) [ | 16 PH | 66.5% | Cephalosporins, penicillins, and macrolides | Respiratory tract complications (e.g., cough), fever, and UTI |
| Barker A.K. et al. (2017) [ | 24 PS | 100.0% | Colds, viral infections, coughs, and sore throat | |
| Mansour O et al. (2017) [ | 173 PH | 85.5% | Tonsillitis | |
| Abood EA et al. (2016) [ | 170 Ph | 25.3%, n = 43 | Amoxicillin (7.3%) | |
| Erku D.A. (2016) [ | 389 Ph | PD: 90.2% | ||
| Kalungia AC et al. (2016) [ | 73 PH | 100% | Amoxicillin (n = 38, 52.1%), cotrimoxazole (n = 18, 24.7%), metronidazole (n = 17, 23.3%) | |
| Khan M.U. et al. (2016) [ | 188 Ph | PD: 63.3% (n = 119) | ||
| Nawab A. Et al. (2016) [ | 50 PH | 12.2% of 100 drugs dispensed without a prescription | Metronidazole and amoxicillin/clavulanate potassium | |
| Bahnassi A. (2015) [ | 147 Ph | 100.0% | Amoxicillin, amoxicillin/clavulanic acid, cephalexin | Sore throat and UTI |
| Dorj G. et al. (2015) [ | 61 PS | PSD: 21.7% (n = 13) | Aminopenicillins, oral (n = 73, 29.9%); aminopenicillins, injection (n = 44, 24.0%); quinolone, oral (n = 30, 24.6%); quinolone, injection (n = 13, 21.3%); cefalosporin, oral (n = 14, 23.0%); cefalosporin, injection (n = 10, 16.4%); macrolides, oral (n = 53, 29.0%); macrolides, injection (n = 29, 15.8%); tetracycline, oral (n = 19, 15.6%) and sulfonamid, oral (n = 18, 29.5%). | Mild/moderate community-acquired pneumonia |
| Shreya Svitlana A. et al. (2015) [ | 100 PH | 100.0% | Cefodoxime (n = 52), amoxicillin (n = 30), doxycycline-doxy (n = 8), cefixime-taxim (n = 10) | Mild toothache |
| Bahnassi A. (2014) [ | 54 Ph | 100.0% | Amoxicillin, amoxicillin/clavulanic acid, azithromycin | Sore throat, sinusitis (pregnant), UTI, ear infection (child), and skin infection |
| Farah R et al. (2014) [ | 100 Ph | 32.0% | Gastrointestinal symptoms, Genito-urinary symptoms, and Respiratory symptoms | |
| Gastelurrutia M.A. et al. (2014) [ | 152 PH | 9.8% of the total number of antibiotics dispensed | ||
| Sabry NA et al. (2014) [ | 36 PH, 1158 INT | 36.4% | Upon pharmacist´s recommendation: Amoxicillin/fluoxacillin (n = 10, 6.58%), ampicillin/sulbactam (n = 10, 6.58%), amoxicillin (n = 8, 5.26%), co-amoxiclav (n = 11, 7.24%), cephalexin (n = 21, 13.82%), cephradine (n = 10, 6.58%), cefaclor (n = 7, 4.61%), cefuroxime (n = 5, 3.29%), cefoperazone (n = 8, 5.26%), cefotaxime (n = 7, 4.61%), ceftriaxone (n = 7, 4.61%), oxycycline (n = 7, 4.61%), tetracycline (n = 3, 1.97%), clarithromycin (n = 4, 2.63%), clindamycin (n = 9, 5.92%), co-trimoxazole (n = 5, 3.29%), ciprofluxacin (n = 7, 4.61%), gatifluxacin (n = 8, 5.26%) and moxifloxacin (n = 5, 3.29%). | Upon pharmacist´s recommendation: UTI (n = 25, 17.86%), sore throat (n = 24, 17.10%), cold & flu (n = 16, 11.40%), toothache (n = 13, 9.29%), infected wound (n = 11, 7.86%), rhinitis (n = 8, 5.70%), acne (n = 8, 5.70%), abdominal cramps (n = 7, 5.00%), tonsillitis (n = 5, 3.57%), post nasal discharges (n = 4, 2.90%), burning (n = 4, 2.90%), asthma (n = 4, 2.90%), food poisoning (n = 4, 2.90%), stomachache (n = 4, 2.90%) and fracture (n = 3, 2.14%). |
| Zapata-Cachafeiro M. et al. (2014) [ | 286 Ph | 64.7%, n = 185 | Urinary and dental infections | |
| Abasaeed AE et al. (2013) [ | 20 Ph, 1645 INT | 26.4% | Ceftriaxone (53.3%), amoxicillin (47.8%), and co-amoxiclav (33.6%) | Cough, influenza, respiratory tract infections, STD, and Helicobacter pylori |
| Rauber C. et al. (2009) [ | 46 Ph | 85.0% | Diseases: Throat infection, UTI, ear infection, sinusitis, pharyngitis, upper airway infection, pneumonia, fever, dental infection, throat plaque, clear and simple infection, skin infection, intestinal infection, cough with secretion, oral infection, and acne. | |
| Nyazema N et al. (2007) [ | 59 PH, 73 PS | PD: 31.0% | Amoxicillin (77%), cotrimoxazole (60%), erythromycin (30%), doxycycline (48%) | |
| Caamaño F et al. (2005) [ | 123 PH, 164 Ph | 65.9% | Clamoxyl® (Amoxicillin) | |
| Caamano Isorna F. et al. (2004) [ | 123 PH, 164 Ph | 65.9% | Clamoxyl® (Amoxicillin) | |
| Chalker J et al. (2002) [ | 44 PH (22 control and 22 intervention) | 51.0% | Cefalexin (Intervention: 57% and Control: 45%) | Simple URTI in a child < 5 years old with a mild cough. |
Sample size: PH, Pharmacies; Ph, Pharmacists; PS, Pharmacy Staff; INT, Interactions; Frequency of antibiotic dispensation without a prescription: PD: Percentage corresponding to pharmacists who report dispensing antibiotics without a prescription calculated using the strategy: 100% less than the percentage of pharmacists who report never dispensing antibiotics without a prescription; PSD: Percentage corresponding to pharmacists who report dispensing antibiotics without a prescription sometimes/occasionally.; PD´: Percentage corresponding to pharmacists who report dispensing antibiotics without a prescription calculated using the strategy: 100% less than the percentage of pharmacists who report never/rarely dispensing antibiotics without a prescription; Types of disease/symptoms most commonly associated with dispensation without a prescription: UTI, Urinary Tract Infection; URTI, Upper Respiratory Tract Infection; STD, Sexually Transmitted Diseases. a Articles that do not explicitly mention throughout the full article that it is about dispensing antibiotics without a prescription, but rather the management of diseases/symptoms in pharmacies/drugstores.
Questions and advice provided when dispensing antibiotics without a prescription.
| Authors (Year) | Questions Asked at the Time of Dispensation | Advice Given at the Time of Dispensation |
|---|---|---|
|
| ||
| Al-Tannir M. et al. (2020) [ | ||
| Halboup A. et al. (2020) [ | ||
| Alrasheedy AA. et al. (2019) [ | ______ | |
| Chang J. et al. (2019) [ | ||
| Damisie G et al. (2019) [ | ______ | |
| Koji EM et al. (2019) [ | Asked about drug allergy history (n = 19); | ______ |
| Mengistu G et al. (2019) [ | None of the pharmacists asked about medication history and nutrition condition | None of the pharmacists provided infomed information about side effects and major interactions |
| Zawahir S et al. (2019) [ | Further questioned about their symptoms or concurrent medical conditions (n = 36, 36.0%) | In 18.0% (n = 44) of the instances, pseudo patients were recommended to see a physician, in about a quarter of them (n = 11, 25.0%) an antibiotic was still provided |
| Erku D.A. et al. (2018) [ | Asked about drug allergies (n = 7, 8.1%) | Instruction on dose and duration (n = 36, 41.9%) |
| Horumpende PG et al. (2018) [ | ______ | None of the pharmacies/retailers voluntarily explained the possible side effects |
| Chang J. et al. (2017) [ | ||
| Marković-Peković V et al. (2017) [ | ______ | |
| ______ | ||
| Okuyan B. et al. (2017) [ | None of the pharmacists asked about drug allergies | None of the pharmacists provided any information about other medications that could be used if an unusual condition occurred or if the patient forgot to take the medication |
| Guinovart MC et al. (2016) [ | In 88 cases (73.9%) the patient was not asked about background of allergies to any antibiotics | Advice to visit a physician (36.1%) |
| Almaaytah A et al. (2015) [ | Asked about drug allergy (n = 26, 17.3%) | Explained how to take the antibiotic (n = 143, 95.3%) |
| Shet A et al. (2015) [ | None of the pharmacists asked about drug allergies | None of the pharmacies provided counseling on expected side effects |
| Alabid A.H.M.A. et al. (2014) [ | Asked “What symptoms have you got?” (n = 29) | ______ |
| Marković-Peković V et al. (2012) [ | ______ | Instructions for use given to the patients were oral (95%), written (78%), both (75.0%), and none (3.0%) |
| Rathnakar U.P. et al. (2012) [ | None of the pharmacists asked about drug allergies | Frequency advised without asking (n = 18) |
| Simó S et al. (2012) [ | None of the pharmacies asked about drug allergies | None of the pharmacies explained the adverse effects |
| Puspitasari HP et al. (2011) [ | In all the scenarios presented (product request for ciprofloxacin 10 tablets 500 mg; product request for 2 capsules tetracycline 250 mg and amoxicillin dry syrups 125 mg per 5 mL), none of the respondents asked about allergies | In the scenarios (product request for ciprofloxacin 10 tablets 500 mg and amoxicillin dry syrups 125 mg per 5 mL), none of the pharmacists informed about side effects, precautions/interactions/contra-indications and the risks of the medicine if not taken |
| Hadi U et al. (2010) [ | The patients were never questioned or referred to a physician | ______ |
| Plachouras D et al. (2010) [ | No comment was made by the pharmacist and no reason for the intended antibiotic use was requested (n = 107, 85.0%) | In the Amoxicillin + clavulanic acid case: n = 3 (4.2%) cases of dispensing, the collaborator was informed by the pharmacist about adverse events or asked whether such events had occurred in the past when the buyer had used antibiotics |
| Llor C et al. (2009) [ | Asked patient about other symptoms (n = 61, 68.5%) | Explained how often to take the antibiotic (n = 74, 83.1%) |
| Wachter DA et al. (1999) [ | In both scenarios, none of the pharmacies asked about drug allergies | ______ |
|
| ||
| Hallit S et al. (2019) [ | Age (80.1%) | Instructed the parents to shake the bottle before each administration (81.2%) |
| Kalungia AC et al. (2016) [ | Asked the indication for using the specific antibiotic requested (94.0%) | Counselled on dosage instructions (n = 70, 95.9%) |
| Bahnassi A. (2015) [ | Asking for the antibiotic indication (36.0%) | No counseling (66.0%) |
| Bahnassi A. (2014) [ | Provided an antibiotic without asking for the indication (36.0%) | Finish the antibiotic even when symptoms are relieved (28.0%) |
| Gastelurrutia M.A. et al. (2014) [ | ______ | Just dispensed (56.9%) |
| Sabry NA et al. (2014) [ | ||
UTI, Urinary Tract Infection; URTI, Upper Respiratory Tract Infection.
Comparison of the frequency of antibiotic dispensation without a prescription between the two methods.
| Country | Simulated Patient Method | Pharmacy Interview/Questionnaire Method |
|---|---|---|
| Saudi Arabia | Al-Tannir M. et al. (2020) [ | Alrasheedy AA. et al. (2019) [ |
| Yemen | Halboup A. et al. (2020) [ | Abood EA et al. (2016) [ |
| Egypt | Abdelaziz AI et al. (2019) [ | Sabry NA et al. (2014) [ |
| Ethiopia | Damisie G et al. (2019) [ | Mengistu G et al. (2019) [ |
| India | Nafade V. et al. (2019) [ | Barker A.K. et al. (2017) [ |
| Sri Lanka | Zawahir S et al. (2019) [ | Zawahir S. et al. (2019) [ |
| Indonesia | Puspitasari HP et al. (2011) [ | Ajie A.A.D. et al. (2018) [ |
| Pakistan | Malik M. et al. (2013) [ | Rehman IU et al. (2018) [ |
| Spain | Zapata-Cachafeiro M et al. (2018) [ | Gastelurrutia M.A. et al. (2014) [ |
| Nepal | Wachter DA et al. (1999) [ | Ansari M. (2017) [ |
| Syria | Al-Faham Z et al. (2011) [ | Mansour O. et al. (2017) [ |
| Malaysia | Alabid A.H.M.A. et al. (2014) [ | Khan M.U. et al. (2016) [ |
| Brazil | Volpato DE et al. (2005) [ | Rauber C. et al. (2009) [ |
| Vietnam | Chalker J et al. (2000) [ | Chalker J et al. (2002) [ |
| Zimbabwe | Nyazema N et al. (2007) [ | Nyazema N et al. (2007) [ |